Know Labs Future Growth

Future criteria checks 0/6

Know Labs's earnings are forecast to decline at 13.7% per annum while its annual revenue is expected to grow at 150.1% per year. EPS is expected to decline by 15.9% per annum.

Key information

-13.7%

Earnings growth rate

-15.9%

EPS growth rate

Medical Equipment earnings growth	17.1%
Revenue growth rate	150.1%
Future return on equity	n/a
Analyst coverage	Low
Last updated	15 Aug 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

NYSEAM:KNW - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2026	6	-22	N/A	-20	1
9/30/2025	N/A	-19	N/A	-15	1
9/30/2024	N/A	-17	-13	-13	N/A
6/30/2024	N/A	-16	-11	-11	N/A
3/31/2024	N/A	-21	-11	-11	N/A
12/31/2023	N/A	-20	-11	-11	N/A
9/30/2023	N/A	-20	-10	-10	N/A
6/30/2023	N/A	-23	-12	-12	N/A
3/31/2023	N/A	-17	-12	-12	N/A
12/31/2022	0	-19	-8	-8	N/A
9/30/2022	4	-20	-8	-7	N/A
6/30/2022	4	-22	-6	-5	N/A
3/31/2022	4	-26	-6	-5	N/A
12/31/2021	4	-25	-8	-7	N/A
9/30/2021	N/A	-25	-7	-7	N/A
6/30/2021	N/A	-22	-6	-6	N/A
3/31/2021	N/A	-18	-6	-5	N/A
12/31/2020	0	-16	-5	-5	N/A
9/30/2020	0	-14	-4	-4	N/A
6/30/2020	0	-12	-4	-4	N/A
3/31/2020	1	-12	-4	-4	N/A
12/31/2019	1	-10	-3	-3	N/A
9/30/2019	2	-8	-3	-3	N/A
6/30/2019	2	-5	-2	-2	N/A
3/31/2019	3	-4	-2	-2	N/A
12/31/2018	4	-3	-1	-1	N/A
9/30/2018	4	-3	-1	-1	N/A
6/30/2018	5	-3	N/A	-1	N/A
3/31/2018	5	-2	N/A	-1	N/A
12/31/2017	5	-2	N/A	-1	N/A
9/30/2017	5	-4	N/A	-1	N/A
6/30/2017	5	-4	N/A	-2	N/A
3/31/2017	6	-3	N/A	-2	N/A
12/31/2016	6	-2	N/A	-3	N/A
9/30/2016	6	-2	N/A	-3	N/A
6/30/2016	6	-3	N/A	-2	N/A
3/31/2016	6	-4	N/A	-1	N/A
12/31/2015	6	-1	N/A	0	N/A
9/30/2015	6	-3	N/A	0	N/A
6/30/2015	7	0	N/A	-1	N/A
3/31/2015	7	1	N/A	-1	N/A
12/31/2014	8	-3	N/A	-2	N/A
9/30/2014	8	-1	N/A	-1	N/A
6/30/2014	8	-2	N/A	-2	N/A
3/30/2014	8	-6	N/A	-3	N/A
12/31/2013	8	-7	N/A	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KNW is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KNW is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KNW is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KNW is forecast to have no revenue next year.

High Growth Revenue: KNW is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if KNW's Return on Equity is forecast to be high in 3 years time

Know Labs Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Know Labs, Inc Announces Executive Appointments

Know Labs Receives Non Compliance Letter from NYSE American Regarding Sections 1003(a)(ii) and 1003(a)(iii)

High number of new and inexperienced directors

Know Labs, Inc. Announces Board and Committee Changes

Know Labs, Inc. has completed a Composite Units Offering in the amount of $3.445 million.

Know Labs, Inc., Annual General Meeting, Sep 26, 2024

Know Labs, Inc. Publishes Clinical Results in Leading Diabetes Journal

Know Labs, Inc. Announces Further Interim Results from a Clinical Research Study

Know Labs, Inc. Announces the Appointment of Chris Somogyi as President, International

Know Labs, Inc. to Present Clinical Research At the 2024 American Association of Clinical Endocrinology Annual Meeting

Know Labs, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Know Labs, Inc. Announces Interim Results from its Most Recent Clinical Research Study

Know Labs, Inc. Announces Board Appointments

Know Labs, Inc. Expands Board of Directors

Know Labs, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Know Labs, Inc., Annual General Meeting, Sep 22, 2023

Know Labs, Inc. Demonstrates Improved Accuracy of Machine Learning Model for Non-Invasive Glucose Monitor

Know Labs Completes Build of Portable Generation 1 Prototype for Non-Invasive Glucose Monitoring

Know Labs, Inc. Furthers External Validation of Bio-RFID(TM) Technology with Study Published in Sensors Journal

Know Labs, Inc. Study Validates Technical Feasibility of Its Novel Sensor for Non-Invasive Glucose Monitoring

Know Labs, Inc. Announces Changes to Executive Leadership Team

Know Labs, Inc. Announces Management Changes

Know Labs Common Stock Deleted from OTC Equity

Know Labs, Inc. has completed an IPO in the amount of $7.2 million.

Know Labs, Inc., Annual General Meeting, Sep 15, 2022

Know Labs, Inc. Announces Executive Appointments

Know Labs, Inc. Announces Executive Appointments

Know Labs Outlines Preparations for Pre-Submission Meeting with FDA

Know Labs, Inc. announced delayed 10-Q filing

Know Labs, Inc. Receives IRB Approval to Begin Internal Clinical Trial of Non-Invasive Glucose Monitoring Technology Bio-RFID™

Know Labs, Inc. Announces Introduction of New KnowU™ Diagnostic Device

Know Labs Receives New Patent for Its Non-Invasive Diagnostic Technology Platform, Bringing Patents Issued and Pending to Nearly 60

Know Labs Announces Successful Results from Pre-Clinical Study Validating Bio-RFID™ Platform Technology

Know Labs, Inc. announced that it has received $14.279 million in funding

Texas Biomedical Research Institute Issues Preliminary Results for Know Labs, Inc.'s Particle Bulb's Ability to Inactivate the SARS-CoV-2 Virus

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies